Home Cart 0 Sign in  
X

[ CAS No. 711007-44-2 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
3d Animation Molecule Structure of 711007-44-2
Chemical Structure| 711007-44-2
Chemical Structure| 711007-44-2
Structure of 711007-44-2 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

Quality Control of [ 711007-44-2 ]

Related Doc. of [ 711007-44-2 ]

Alternatived Products of [ 711007-44-2 ]
Product Citations

Product Details of [ 711007-44-2 ]

CAS No. :711007-44-2 MDL No. :MFCD09029906
Formula : C7H9N3O Boiling Point : -
Linear Structure Formula :- InChI Key :NAWJZCSEYBQUGY-UHFFFAOYSA-N
M.W : 151.17 Pubchem ID :10487029
Synonyms :

Calculated chemistry of [ 711007-44-2 ]      Expand+

Physicochemical Properties

Num. heavy atoms : 11
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.0
Num. rotatable bonds : 1
Num. H-bond acceptors : 1.0
Num. H-bond donors : 3.0
Molar Refractivity : 43.35
TPSA : 95.13 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -7.46 cm/s

Lipophilicity

Log Po/w (iLOGP) : 0.7
Log Po/w (XLOGP3) : -0.33
Log Po/w (WLOGP) : -0.03
Log Po/w (MLOGP) : 0.0
Log Po/w (SILICOS-IT) : -0.46
Consensus Log Po/w : -0.02

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -0.91
Solubility : 18.7 mg/ml ; 0.124 mol/l
Class : Very soluble
Log S (Ali) : -1.21
Solubility : 9.4 mg/ml ; 0.0622 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -1.25
Solubility : 8.48 mg/ml ; 0.0561 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.0

Safety of [ 711007-44-2 ]

Signal Word:Danger Class:6.1
Precautionary Statements:P273-P280-P301+P310 UN#:2811
Hazard Statements:H301-H312+H332-H317-H319-H341-H351-H371-H411 Packing Group:
GHS Pictogram:

Application In Synthesis of [ 711007-44-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 711007-44-2 ]
  • Downstream synthetic route of [ 711007-44-2 ]

[ 711007-44-2 ] Synthesis Path-Upstream   1~11

  • 1
  • [ 313279-12-8 ]
  • [ 711007-44-2 ]
YieldReaction ConditionsOperation in experiment
98% With hydrogen In methanol at 20℃; for 5 h; SYNTHESIS EXAMPLESNo. 1-1: 2-[chloro(difluoro)methyl]-1H-benzimidazole-4-carboxamide; 2-Amino-3-nitrobenzoic acid (3.00 g, 16.47 mmol) was dissolved in dimethoxyethane (15 ml), thionyl chloride was added (2.61 g, 21.91 mmol), and the mixture was stirred at 50° C. for 12 h. Subsequently, the reaction mixture was concentrated under reduced pressure, the solvent was removed and then toluene was added, and the mixture was concentrated again. Thereafter, aqueous saturated ammonia solution (40 ml) was initially charged in a round-bottom flask and cooled to 10° C., and the acid chloride (3.30 g, 16.45 mmol) from the first step, which had not been purified any further, was added dropwise while stirring vigorously. In the course of this, the temperature of the reaction mixture was kept below 40° C. After the end of the addition, the reaction mixture was stirred at 50° C. for one hour, then diluted with water and stirred at room temperature. By filtering off the orange precipitate which formed with suction, washing with water and drying, 2-amino-3-nitrobenzamide (2.60 g, 87percent) was obtained. 2-Amino-3-nitrobenzamide (2.60 g, 14.35 mmol) was then added in a metal vessel to palladium on carbon (water-moist catalyst, 10percent Pd, 0.05 equiv., 0.072 mmol) in methanol (80 ml). In a laboratory reactor, hydrogen was introduced into the metal vessel and the resulting reaction mixture was stirred at room temperature at a pressure of 2 bar for 5 h. After complete conversion, the catalyst was filtered off through Celite and washed with methanol. The filtrate was concentrated under reduced pressure and the residue was extracted with water and ethyl acetate. The combined organic phases were dried over magnesium sulfate, filtered and concentrated under reduced pressure. The resulting crude product did not need any further purification and contained 2,3-diaminobenzamide (2.15 g, 98percent) in a purity of >95percent. 2,3-Diaminobenzamide (200 mg, 1.32 mmol) was dissolved in chlorodifluoroacetic acid (3 ml) with vigorous stirring. The resulting reaction mixture was subsequently stirred under reflux for 3 h. After cooling to room temperature, NaHCO3 solution was added. In the course of this, the 2-[chloro(difluoro)methyl]-1H-benzimidazole-4-carboxamide target product (190 mg, 58percent) precipitated out as a colorless solid, which was filtered off with suction, washed with water and finally dried. 1H NMR (400 MHz, d6-DMSO δ, ppm) 14.40 (br. s, 1H, NH), 8.72 (br. s, 1H, NH), 8.02 (m, 1H, NH), 7.92 (m, 1H), 7.74 (m, 1H), 7.55 (m, 1H); 13C NMR (150 MHz, d6-DMSO δ, ppm) 165.5, 147.9, 139.1, 134.2, 124.9, 124.5, 123.9, 118.4-122.2 (t, CF2Cl), 116.6.
98% With palladium 10% on activated carbon; hydrogen In methanol; water at 20℃; for 5 h;   2-Amino-3-nitrobenzoic acid (3.00 g, 16.47 mmol) was dissolved in   dimethoxyethane (15 ml),   thionyl chloride was added (2.61 g, 21.91 mmol), and the mixture was stirred at 50°C for 12 h. Subsequently, the reaction mixture was concentrated under reduced pressure, the solvent was removed and then   toluene was added, and the mixture was concentrated again. Thereafter, aqueous saturated   ammonia solution (40 ml) was initially charged in a round-bottom flask and cooled to 10°C, and the   acid chloride (3.30 g, 16.45 mmol) from the first step, which had not been purified any further, was added dropwise while stirring vigorously. In the course of this, the temperature of the reaction mixture was kept below 40°C. After the end of the addition, the reaction mixture was stirred at 50°C for one hour, then diluted with water and stirred at room temperature. By filtering off the orange precipitate which formed with suction, washing with water and drying, 2-amino-3-nitrobenzamide (2.60 g, 87percent) was obtained.   2-Amino-3-nitrobenzamide (2.60 g, 14.35 mmol) was then added in a metal vessel to   palladium on carbon (water-moist catalyst, 10percent Pd, 0.05 equiv., 0.072 mmol) in   methanol (80 ml). In a laboratory reactor,   hydrogen was introduced into the metal vessel and the resulting reaction mixture was stirred at room temperature at a pressure of 2 bar for 5 h. After complete conversion, the catalyst was filtered off through Celite and washed with methanol. The filtrate was concentrated under reduced pressure and the residue was extracted with water and ethyl acetate. The combined organic phases were dried over magnesium sulfate, filtered and concentrated under reduced pressure. The resulting crude product did not need any further purification and contained   2,3-diaminobenzamide (2.15 g, 98percent) in a purity of > 95percent. 2,3-Diaminobenzamide (200 mg, 1.32 mmol) was dissolved in   chlorodifluoroacetic acid (3 ml) with vigorous stirring. The resulting reaction mixture was subsequently stirred under reflux for 3 h. After cooling to room temperature,   NaHCO3 solution was added. In the course of this, the   2-[chloro(difluoro)methyl]-1H-benzimidazole-4-carboxamide target product (190 mg, 58percent) precipitated out as a colorless solid, which was filtered off with suction, washed with water and finally dried. 1H NMR (400 MHz, d6-DMSO δ, ppm) 14.40 (br. s, 1H, NH), 8.72 (br. s, 1H, NH), 8.02 (m, 1H, NH), 7.92 (m, 1H), 7.74 (m, 1H), 7.55 (m, 1H); 13C NMR (150 MHz, d6-DMSO δ, ppm) 165.5, 147.9, 139.1, 134.2, 124.9, 124.5, 123.9, 118.4-122.2 (t, CF2Cl), 116.6.
53% With ammonium formate In methanol at 40℃; for 2 h; Pd/C (200 mg) is added to a stirred mixture of 2-amino-3- nitrobenzamide (1.81 g, 10.0 mmoles) or 2-AMINO-3-NITRO- (N- substituted) -benzamide and ammonium-formiate (3.78 g, 0.06 mol) in methanol (40 mL) or some other appropriate solvent and the mixture is stirred at 40 °C for 2 hours. The mixture is then filtered through Cellite, washed with methanol (40 mL) or the used solvent, evaporated and the residue is purified by way of crystallyzation or flash column chromatography to give 2,3-diaminobenzamide as a pale brown light sensitive solid (800 mg, 53 percent), MP 103-105 °C ; v max (CM-1) 3330,3170, 1630, 1600, MS m/z (percent) : 151 (M+, 70), 134 (72), 106 (100) 79 (38). The same method can be used for 2, 3-DIAMINO- (N-SUBSTITU- ted) benzamides
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2004, vol. 14, # 10, p. 2433 - 2437
[2] Patent: US2011/218103, 2011, A1, . Location in patent: Page/Page column 11
[3] Patent: EP2561759, 2013, A1, . Location in patent: Paragraph 0051
[4] Patent: WO2004/96793, 2004, A1, . Location in patent: Page 14
[5] Journal of Medicinal Chemistry, 2000, vol. 43, # 22, p. 4084 - 4097
[6] Patent: WO2007/6566, 2007, A1, . Location in patent: Page/Page column 28; 33
[7] Organic Process Research and Development, 2007, vol. 11, # 4, p. 693 - 698
[8] European Journal of Medicinal Chemistry, 2017, vol. 138, p. 1135 - 1146
  • 2
  • [ 19613-80-0 ]
  • [ 711007-44-2 ]
Reference: [1] Journal of Medicinal Chemistry, 2005, vol. 48, # 6, p. 1873 - 1885
  • 3
  • [ 1314951-83-1 ]
  • [ 711007-44-2 ]
Reference: [1] Patent: US6737421, 2004, B1, . Location in patent: Page column 11
[2] Patent: EP1391457, 2004, A1, . Location in patent: Page 37
  • 4
  • [ 603-81-6 ]
  • [ 711007-44-2 ]
Reference: [1] Patent: CN105712937, 2016, A, . Location in patent: Paragraph 0015
[2] Patent: CN107556288, 2018, A, . Location in patent: Paragraph 0022; 0023; 0024
  • 5
  • [ 606-18-8 ]
  • [ 711007-44-2 ]
Reference: [1] Journal of Medicinal Chemistry, 2000, vol. 43, # 22, p. 4084 - 4097
[2] Patent: US2011/218103, 2011, A1,
[3] Patent: EP2561759, 2013, A1,
[4] Organic Process Research and Development, 2007, vol. 11, # 4, p. 693 - 698
[5] European Journal of Medicinal Chemistry, 2017, vol. 138, p. 1135 - 1146
  • 6
  • [ 131645-73-3 ]
  • [ 711007-44-2 ]
Reference: [1] Journal of Medicinal Chemistry, 2000, vol. 43, # 22, p. 4084 - 4097
[2] Patent: US2011/218103, 2011, A1,
[3] Organic Process Research and Development, 2007, vol. 11, # 4, p. 693 - 698
  • 7
  • [ 110-91-8 ]
  • [ 610-30-0 ]
  • [ 711007-44-2 ]
Reference: [1] Patent: EP300366, 1989, A1,
  • 8
  • [ 15147-64-5 ]
  • [ 711007-44-2 ]
Reference: [1] Journal of Medicinal Chemistry, 2005, vol. 48, # 6, p. 1873 - 1885
  • 9
  • [ 77326-45-5 ]
  • [ 711007-44-2 ]
Reference: [1] Journal of Medicinal Chemistry, 2000, vol. 43, # 22, p. 4084 - 4097
  • 10
  • [ 603-11-2 ]
  • [ 711007-44-2 ]
Reference: [1] Organic Process Research and Development, 2007, vol. 11, # 4, p. 693 - 698
[2] Organic Process Research and Development, 2007, vol. 11, # 4, p. 693 - 698
  • 11
  • [ 641-70-3 ]
  • [ 711007-44-2 ]
Reference: [1] Organic Process Research and Development, 2007, vol. 11, # 4, p. 693 - 698
[2] Organic Process Research and Development, 2007, vol. 11, # 4, p. 693 - 698
Recommend Products
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 711007-44-2 ]

Aryls

Chemical Structure| 39549-79-6

[ 39549-79-6 ]

2-Amino-4-methylbenzamide

Similarity: 0.95

Chemical Structure| 40545-33-3

[ 40545-33-3 ]

2-Amino-5-methylbenzamide

Similarity: 0.93

Chemical Structure| 88-68-6

[ 88-68-6 ]

2-Aminobenzamide

Similarity: 0.93

Chemical Structure| 1885-32-1

[ 1885-32-1 ]

2-Amino-3-methylbenzamide

Similarity: 0.91

Chemical Structure| 2835-68-9

[ 2835-68-9 ]

4-Aminobenzamide

Similarity: 0.86

Amides

Chemical Structure| 39549-79-6

[ 39549-79-6 ]

2-Amino-4-methylbenzamide

Similarity: 0.95

Chemical Structure| 40545-33-3

[ 40545-33-3 ]

2-Amino-5-methylbenzamide

Similarity: 0.93

Chemical Structure| 88-68-6

[ 88-68-6 ]

2-Aminobenzamide

Similarity: 0.93

Chemical Structure| 1885-32-1

[ 1885-32-1 ]

2-Amino-3-methylbenzamide

Similarity: 0.91

Chemical Structure| 2835-68-9

[ 2835-68-9 ]

4-Aminobenzamide

Similarity: 0.86

Amines

Chemical Structure| 39549-79-6

[ 39549-79-6 ]

2-Amino-4-methylbenzamide

Similarity: 0.95

Chemical Structure| 40545-33-3

[ 40545-33-3 ]

2-Amino-5-methylbenzamide

Similarity: 0.93

Chemical Structure| 88-68-6

[ 88-68-6 ]

2-Aminobenzamide

Similarity: 0.93

Chemical Structure| 1885-32-1

[ 1885-32-1 ]

2-Amino-3-methylbenzamide

Similarity: 0.91

Chemical Structure| 2835-68-9

[ 2835-68-9 ]

4-Aminobenzamide

Similarity: 0.86